Why the study?
Does female sex affect mortality and complication rates in patients undergoing TAVR compared to male sex?
Does female sex affect mortality and complication rates in patients undergoing TAVR compared to male sex?
Answers are grounded in this paper and cite their sources.
Women undergoing TAVR face higher 30-day mortality and bleeding risks compared to men, but this early hazard reverses by 1 year into a long-term survival advantage.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Filippo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: